Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000169293 | SCV000220611 | likely pathogenic | Fanconi anemia complementation group C | 2014-08-20 | criteria provided, single submitter | literature only | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000169293 | SCV000695435 | pathogenic | Fanconi anemia complementation group C | 2017-08-14 | criteria provided, single submitter | clinical testing | Variant summary: The FANCC c.65G>A (p.Trp22X) variant results in a premature termination codon, predicted to cause a truncated or absent FANCC protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g.c.67delG/p.Asp23fsX23, c.1642C>T/p.Arg548X). One in silico tool predicts a damaging outcome for this variant. This variant was found in 1/121148 control chromosomes at a frequency of 0.0000083, which does not exceed the estimated maximal expected allele frequency of a pathogenic FANCC variant (0.0017678). This variant has been reported in at least three patients with Fanconi Anemia. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic/likely pathogenic. Taken together, this variant is classified as pathogenic. |
Fulgent Genetics, |
RCV000169293 | SCV000894485 | pathogenic | Fanconi anemia complementation group C | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000169293 | SCV001163260 | pathogenic | Fanconi anemia complementation group C | 2023-12-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001390247 | SCV001591920 | pathogenic | Fanconi anemia | 2023-12-26 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Trp22*) in the FANCC gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FANCC are known to be pathogenic (PMID: 17924555). This variant is present in population databases (rs377294947, gnomAD 0.008%). This premature translational stop signal has been observed in individual(s) with clinical features of Fanconi anemia (PMID: 8844212, 28717661). ClinVar contains an entry for this variant (Variation ID: 188926). For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV002362865 | SCV002663424 | pathogenic | Hereditary cancer-predisposing syndrome | 2024-08-14 | criteria provided, single submitter | clinical testing | The p.W22* pathogenic mutation (also known as c.65G>A), located in coding exon 1 of the FANCC gene, results from a G to A substitution at nucleotide position 65. This changes the amino acid from a tryptophan to a stop codon within coding exon 1. This alteration has been identified in the homozygous state in several patients with Fanconi Anemia (Gibson RA et al. Hum Mutat. 1996;8:140-8; Ameziane N et al. Hum Mutat. 2008 Jan;29:159-66; Pilonetto DV et al. Mol Genet Genomic Med. 2017 Jul;5:360-372). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Prevention |
RCV003407628 | SCV004106264 | pathogenic | FANCC-related disorder | 2023-04-10 | criteria provided, single submitter | clinical testing | The FANCC c.65G>A variant is predicted to result in premature protein termination (p.Trp22*). This variant has been reported in the homozygous state in at least two patients with Fanconi anaemia (Gibson et al. 1996. PubMed ID: 8844212; Ameziane et al. 2008. PubMed ID: 17924555). This variant is reported in 0.011% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/9-98011509-C-T). Nonsense variants in FANCC are expected to be pathogenic. This variant is interpreted as pathogenic. |
Gene |
RCV004719732 | SCV005325764 | pathogenic | not provided | 2023-09-25 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 34774576, 29922827, 17924555, 12670332, 28717661, 8844212, 27832981, Rodriguez2005[article]) |
Leiden Open Variation Database | RCV000169293 | SCV001365307 | pathogenic | Fanconi anemia complementation group C | 2020-02-28 | no assertion criteria provided | curation | Curator: Arleen D. Auerbach. Submitters to LOVD: Arleen D. Auerbach, Daniela Pilonetto, Johan de Winter. |
Natera, |
RCV001390247 | SCV002081314 | pathogenic | Fanconi anemia | 2017-03-17 | no assertion criteria provided | clinical testing |